Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company’s public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Etiology of Community-Acquired Pneumonia

Anucha Apisarnthanarak, MD\textsuperscript{a}, Linda M. Mundy, MD\textsuperscript{b,*}

\textsuperscript{a}Division of Infectious Diseases, Thammasart University Hospital, Pratumthani 12120, Thailand
\textsuperscript{b}Division of Infectious Diseases, Washington University School of Medicine, 660 South Euclid Avenue, Campus Box 8051, St. Louis, MO 63110, USA

Despite recent advances in diagnosis and treatment, community-acquired pneumonia (CAP) is still a common and potentially lethal infectious disease. CAP is the leading cause of death from infectious diseases and the sixth-ranked cause of death overall in the United States\textsuperscript{[1]}. It is estimated that 4 to 5 million cases of CAP occur annually, accounting for approximately 10 million physician visits, 500,000 hospitalizations, 45,000 deaths, and an annual cost of $23 billion \textsuperscript{[2,3]}. The overall CAP-related mortality rate has ranged from 2% to 30% among hospitalized patients, whereas the mortality rate is less than 1% for patients who are not hospitalized \textsuperscript{[2]}. Disputes over diagnostic evaluations and therapeutic decisions exist for patients with CAP \textsuperscript{[1]}. The causative pathogen remains unknown in 30% to 60% of cases despite vigorous clinical investigation \textsuperscript{[4]}. Based on a review of more than 15 published reports from North America covering more than two decades of experience in hospitalized patients, the detection of specific bacterial pathogens as causes of pneumonia ranges from 20% to 60% for \textit{Streptococcus pneumoniae}, 3% to 10% for \textit{Haemophilus influenzae}, 1% to 6% for \textit{Mycoplasma pneumoniae}, 4% for \textit{Chlamydia pneumoniae}, 2% to 8% for \textit{Legionella} species, 2% for viruses, 6% to 10% for aspiration, 3% for \textit{Staphylococcus aureus}, 3% to 5% for gram-negative bacilli, and 10% to 20% for other identified causes \textsuperscript{[1]}. This article summarizes the epidemiology, risk factors, and outcomes of microorganisms associated with CAP.

Etiology of community-acquired pneumonia

At least six important host defense mechanisms are important in the prevention of CAP: aerodynamic filtration, the cough reflex, mucociliary transport, phagocytic cell function, immunologic function, and the clearance of pulmonary secretions. Deficiencies in normal host defense mechanisms influence the epidemiology, risk factors, and outcomes for CAP \textsuperscript{[5]}. The etiology of CAP can be defined broadly into typical pathogens (eg, \textit{S pneumoniae}, \textit{H influenzae}, and \textit{Moraxella catarrhalis}), atypical pathogens (eg, \textit{Legionella} spp, \textit{M pneumoniae}, \textit{C pneumoniae}), viruses, aspiration, and other agents. The etiologic agents and risk factors of common CAP pathogens for immunocompetent hosts are summarized in Table 1. In immunocompromised hosts, in addition to the usual pathogens, the etiology of CAP also includes opportunistic infections, such as \textit{Mycobacterium tuberculosis}, \textit{Pneumocystis jiroveci} pneumonia (PCP), and other opportunistic fungal infections (Table 2). Coexisting pulmonary pathogens should be considered when clinical isolates have been detected, when patients lack clinical improvement, and when patients have clinical deterioration despite seemingly appropriate treatment.

Typical pathogens

\textit{Streptococcus pneumoniae}

\textbf{Epidemiology}

\textit{S pneumoniae} is among the leading infectious causes of illness and death from CAP worldwide for young children, for persons who have underlying...
chronic systemic conditions, and for the elderly. The pneumococcus had been identified in 5% to 11% of patients with CAP treated on an ambulatory basis, in 5% to 42.8% of patients with CAP who require hospitalization, and in 11% to 37.5% of patients with CAP who require admission to an intensive care unit (ICU) [4,6–9]. In a meta-analysis of 122 reports of CAP from 1966 through 1995, *S pneumoniae* accounted for the majority of over 7000 cases (66%) in which an etiologic diagnosis was made and for 66% of the lethal pneumonias[10]. In addition, the pneumococcus is the most common cause (60%) of bacteremic pneumonia[7].

**Risk factors**

Specific risk factors for pneumococcal infection include dementia, seizure disorders, congestive heart failure, cerebrovascular disease, chronic obstructive pulmonary disease (COPD), HIV, black race, over-crowding in institutions, and smoking [11–12]. In the United States, nonsusceptibility to penicillin has increased significantly during the past decade [13]. Frequently, rates of penicillin-resistant *S pneumoniae* (PRSP) are in excess of 30% [14]. The minimal inhibitory concentrations (MICs) for most strains with high-level resistance are 2 to 4 μg/mL. Of concern, the increasing rate of penicillin resistance is associated with resistance to beta-lactams and other classes of antibiotics, such as macrolides, tetracycline, and trimethoprim-sulfamethoxazole [14]. With the increase in the rate of PRSP, physicians should be aware of the changing epidemiology and microbiology of pneumococcal disease to provide appropriate empiric antimicrobial treatment.

### Table 1

| Etiology                  | Ambulatory setting | Hospitalization setting | Nursing home setting | ICU setting | Risk factors                                      |
|---------------------------|--------------------|-------------------------|----------------------|-------------|---------------------------------------------------|
| **Bacteria**              |                    |                         |                      |             |                                                   |
| *Streptococcus pneumonia* | 5%–11%             | 5%–42.8%                | 6%–29.8%             | 11%–37.5%   | Black race, smoking, seizure disorder, dementia, COPD, CHF, HIV |
| *Haemophilus influenzae*  | 2%–12%             | 1%–11%                  | 2.5%–19%             | —           | COPD, prior antibiotic, oral steroida              |
| *Staphylococcus aureus*   | —                  | 1%–5%                   | 1.7%–26%             | 3%–18%      | Advanced age, prolonged hospitalization, prior antibiotic, several comorbidities |
| Gram-negative bacilli     | —                  | 0.7%–7%                 | 5.3%–23%             | 3%–25%      | Bronchiectasis, malignancy, CF, aplastic anemia   |
| *Moraxella catarrhalis*   | —                  | —                       | 3.8%–5.5%            | —           | *COPD, bronchiectasis, CHF, DM, malignancy, oral steroid* |
| **Atypical agents**       |                    |                         |                      |             |                                                   |
| *Legionella pneumophila*  | —                  | 2%–6%                   | —                    | 3%–22.8%    | Renal and hepatic failure, DM, exposureb, recent travelc |
| *Mycoplasma pneumoniae*   | 17.4%–37%          | 2%–32.5%                | —                    | —           | Contact with patient with similar symptoms         |
| *Chlamydia pneumoniae*    | 5.3%–10.7%         | 5%–17.9%                | 6.6%                 | —           | Advanced age, several comorbidities                |
| Aspiration                | —                  | —                       | 14.5%                | —           |                                                   |
| Unknown                   | 41%–55%            | —                       | 13%–76.7%            | 25%–41.2%   |                                                   |

*Abbreviations: CF, cystic fibrosis; CHF, congestive heart failure; DM, diabetes mellitus.*

| a History of steroid use within the past 3 months. |
| b Exposure to hot tub and whirlpool-type spas, including recent repair with plumbing. |
| c Recent travel with an overnight stay outside the home. |

### Haemophilus influenzae

**Epidemiology**

*Haemophilus influenzae*, a fastidious gram-negative cocobacillus bacteria, is the third most common cause of CAP identified in patients who require hospitalization [6]. *H influenzae* accounts for 2% to 12% of CAP in patients treated on an ambulatory basis, 1% to 11% of CAP in patients who require hospitalization, and 3% to 19% of pneumonic cases in nursing home residents [4,6–9]. Most *H influenzae* clinical isolates are nontypeable stains recovered
from patients during the winter months [3]. In a meta-
analysis of 33,148 patients from 127 studies, 
*H influenzae* was the cause in 844 (3%) patients [10].

Risk factors

Most studies have shown a higher prevalence of 
*H influenza* pneumonia among patients with COPD 
[15]. Other risk factors include the use of antibiotics 
or oral steroids within the past 3 months [6]. Currently, 
more than 30% of *H influenzae* isolates in 
Canada have aminopenicillin resistance owing to 
β-lactamase production [16]. Nearly all strains are 
susceptible to ceftriaxone and cefuroxime, yet more 
than 50% of β-lactamase–producing *H influenza* 
isolates display either intermediate or high-level or 
resistance to clarithromycin [17].

**Moraxella catarrhalis**

**Epidemiology**

Approximately 1% to 5% of healthy adults are 
colonized by *M catarrhalis* [18,19]. Adults with 
chronic lung disease have been reported to have 
higher rates of *M catarrhalis* respiratory tract colo-
zation when compared with healthy adults [18]. A 
study of adult carrier rates of *M catarrhalis* showed 
differential rates by age, that is, 5% versus 27% for 
adults aged less and more than 60 years, respectively 
[19]. Three separate but related clinical scenarios 
have been defined for *M catarrhalis* lower respiratory 
tract infections: (1) infection causing a COPD 
exacerbation, (2) infection causing pneumonia, espe-
cially in an older adult, and (3) infection as a noso-
comial respiratory tract pathogen [18]. *M catarrhalis* 
pneumonia occurs predominantly in the winter 
months and is responsible for 4% to 6% of nursing 
home–acquired pneumonia and 10% of CAP in the 
elderly [3,19].

**Risk factors**

Most elderly patients who experience pneumonia 
owing to *M catarrhalis* have underlying cardiopul-
monary disease, including COPD, bronchiectasis, 
congestive heart failure, or predisposition to aspira-

---

**Table 2**

| Etiology                            | Area of endemcity | Incidence       | Risk factors                                                                                                                                 |
|-------------------------------------|-------------------|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------|
| **Bacterial**                       | Ubiquitous        | 1.9–19.2 cases/100 patient-years | Decreasing CD4 cell counts, injection drug use, prior sinusitis and respiratory tract infection, use of TMP-SMXd                             |
| **Mycobacterial**                   | Ubiquitous        | 1.4–16.2 cases/100 patient-years | Injection drug use, homeless, PPD skin test positive                                                                                       |
| **Opportunistic fungal infections** |                   |                 |                                                                                                                                             |
| *Pneumocystis jiroveci*             | Ubiquitous        | 0.22–4.6 cases/100 patient-years | CD4 <200 cells/mm³, clinical marker², the occurrence of previous pneumonia and AIDS-defining illness CD4 <100 cells/mm³, black race, injection drug use, cigarette smoking |
| **Cryptococcus neoformans**         | Ubiquitous        | ND              | Age, underlying immunosuppression                                                                                                           |
| **Histoplasma capsulatum**          | North American river valleys, Europe, Africa, Southeast Asia, Caribbean, Central and South America Argentina, Central America | 1%–25%a |                                                                                                                                             |
| **Coccidioides immitis**            | Southwestern United States, Northwestern Mexico | 0.3%–8.2%b | CD4 <250 cells/mm³, clinical diagnosis of AIDS                                                                                             |
| **Penicillium marneefii**           | Southern China, Hong Kong, Thailand, Vietnam | 15%–20%c | Exposure to environmental reservoirsf                                                                                                         |

**Abbreviations:** ND, no data; PPD, purified protein derivative; TMP-SMX, trimethoprim-sulfamethoxazole.

¹ Incidence varies from <1% of patients in nonendemic areas to 25% of patients in endemic areas.

² Incidence varies from 0.3% nationwide (United States) to 8.2% in Arizona.

³ Accounting for 15% to 20% of all AIDS-related illness in Northern Thailand.

⁴ This factor was found to be protective.

⁵ Including wasting syndrome, the occurrence of a previous episode of pneumonia of any type, or the occurrence of previous AIDS-defining events.

⁶ Occupational or other exposure to soil in Northern Thailand.
Other predisposing conditions associated with *M. catarrhalis* infection include corticosteroid therapy, diabetes mellitus and malignancies [18]. Although *M. catarrhalis* pneumonia causes a significant illness in elderly patients, fulminant pneumonia, pleural effusion, and empyema are uncommon [18]. Most (90%) strains of *M. catarrhalis* produce an inducible β-lactamase [21]. The β-lactamase is more active against penicillins than cephalosporins, and its activity is inhibited by β-lactamase inhibitors. These strains show an inoculum-dependent susceptibility to ampicillin; therefore, ampicillin should not be used for these strains regardless of the results of susceptibility testing.

**Staphylococcus aureus**

*Epidemiology*

Pneumonia owing to *S. aureus* accounts for 1% to 5% of patients with CAP who require hospitalization and 2% to 26% of patients with nursing home–acquired pneumonia [4,6–9]. Clinical manifestations are similar to those with CAP from other bacterial etiologies [22,23], although the mortality may be higher [23,24]. Radiologic patterns are protean, inclusive of cavity formations [23,25]. Methicillin-resistant *S. aureus* (MRSA) remains more of a concern for hospital-acquired pneumonia (HAP), although it has been reported as a cause in CAP [23,24].

*Risk factors*

The risk factors associated with *S. aureus* pneumonia include advanced age, prolonged hospitalization, underlying lung disease, prior antibiotic therapy, and surgery or other invasive procedures [22,24]. MRSA pneumonia tends to produce a significantly greater frequency of bacteremia and septic shock and may associated with higher mortality [22].

**Aerobic gram-negative pneumonia**

*Epidemiology*

Aerobic gram-negative pneumonia accounts for 1% to 7% of patients with CAP who require hospitalization and 5% to 23% of HAP and nursing home–acquired pneumonia [4,6–9]. These pathogens also have been identified in severe CAP; although rare, such cases often are rapidly progressive and may be fatal [26].

*Risk factors*

Aerobic gram-negative pneumonia, especially with *Pseudomonas aeruginosa*, is a prognostic indicator of mortality in patients with CAP. Most cases occur in patients with underlying diseases, such as malignancy, cystic fibrosis, aplastic anemia, and bronchiectasis [9]. Environmental exposure to dusts containing metals such as iron have been associated with *Acinetobacter* CAP, whereas exposure to water aerosolization has been associated with *P. aeruginosa* pneumonia [26].

**Anaerobic bacterial pneumonia**

*Epidemiology*

The frequency of anaerobic infection among patients with CAP is not known, because the methods required to obtain valid uncontaminated specimens for meaningful anaerobic culture have rarely been used. Nonetheless, anaerobic bacteria are the most common etiologic agents of lung abscess and aspiration pneumonia, and these bacteria are relatively common isolates from empyemas [3,27]. Patients with anaerobic bacterial infection may also present with pneumonitis that is indistinguishable from other forms of bacterial pneumonia [28].

*Risk factors*

Factors that predispose to anaerobic bacterial pneumonia include aspiration, infection of the gingival crevice (gingivitis), necrosis of tissue with abscess formation or bronchopulmonary fistula, infection complicating airway obstruction, and infection in a dependent pulmonary segment [27]. Some studies have suggested that anaerobes may account for a substantial number of cases of CAP that have these characteristic features [29].

**Atypical pathogens**

*Mycoplasma pneumoniae*

*Epidemiology*

*M. pneumoniae* is a common cause of respiratory tract infection in young adults, attributable for 17% to 37% of outpatient CAP and 2% to 33% of patients with CAP who require hospitalization [5–9]. After an incubation period of 2 to 4 weeks, approximately 3% of patients have clinical and radiographic evidence of pneumonia. Common symptoms include a prodromal period with fever, chills, headache, and sore throat followed by a dry nocturnal or productive cough of mucoid sputum that persists for 3 to 4 weeks [3]. Extrapulmonary manifestations may include hemolytic anemia, nausea and vomiting, myocarditis, rash, and diverse neurologic syndromes.
Risk factors

A possible clue to help diagnose *M pneumoniae* pneumonia is a history of contact with a person with a similar condition characterized by a long incubation period. Currently, there is no reliable diagnostic test to detect *M pneumoniae* infection; therefore, macrolide or tetracycline-based therapy usually is empirical.

Chlamydia pneumoniae

Epidemiology

The prevalence of pneumonia owing to *C pneumoniae* varies from year to year and within geographic settings. Studies indicate that *C pneumoniae* is linked to 5% to 11% of patients with CAP who are treated on an ambulatory basis, 5% to 18% of patients with CAP who require hospitalization, and approximately 7% of patients with nursing home–acquired pneumonia [5–9]. The clinical spectrum ranges from asymptomatic infection to life-threatening pneumonia. When seen in CAP as one of two pathogens, the associated pathogen seems to influence the clinical course and outcome [30].

Risk factors

In *C pneumoniae* pneumonia, sore throat, hoarseness, and headache are important nonpneumonic symptoms; other findings include sinusitis, reactive airway disease, and empyema [3]. Advanced age and several comorbidities are risk factors for hospitalization in patients with pneumonia owing to *C pneumoniae* [3]. The preferred diagnostic test is an assay of acute and convalescent specimens to detect a fourfold increase in antibody titers, with supporting evidence based on throat swab polymerase chain reaction or culture results [3,31]. Nevertheless, with the limitation and availability of diagnostic tests, treatment most often is empirical.

Legionella pneumophila and other Legionella species

Epidemiology

*Legionella* species are implicated in 2% to 6% of patients with CAP who require hospitalization [7–8]. Although rare in immunocompetent adults younger than 30 years of age, legionellosis can be a major cause of lethal pneumonia, with mortality rates of 5% to 25% among immunocompetent hosts and substantially higher rates among immunosuppressed hosts [32]. Clinical features of Legionnaires’ disease include high fever, hyponatremia, central nervous system manifestations, elevated lactate dehydrogenase levels, and the presence of severe disease [32].

Risk factors

Epidemiologic risk factors for Legionnaires’ disease include recent travel with an overnight stay outside the home, recent repair of domestic plumbing, exposure to hot tub and whirlpool-type spas, renal or hepatic failure, diabetes, or systemic malignancy [33,34]. In addition, increasing age, smoking, and compromised cell-mediated immunity are associated with Legionnaires’ disease [33]. Diagnostic tests for Legionnaires’ disease include the urine antigen assay for *L pneumophila* serogroup 1 and culture on selective media, which detects all *Legionella* strains but is technically demanding [3].

Miscellaneous causes of community-acquired pneumonia

A wide variety of pathogens, such as *M tuberculosis*, fungi, viruses, nocardia, *Chlamydia psittaci*, Hantavirus, *Coxiella burnetti*, *P jiroveci*, *Leptospira*, and uncommon pathogens such as tularemia may be responsible for CAP, depending on the patient’s host defense system and exposures. Physicians should consider epidemiologic risk factors in the diagnosis and treatment of CAP, especially in patients who do not respond to a standard therapeutic regimen for CAP (Table 3).

Community-acquired pneumonia and HIV/AIDS

Immunocompromised patients, especially those with HIV infection, have increased risk for routine and unusual CAP pathogens. The etiology of CAP in immunocompromised patients, with a focus on hosts with HIV infection, has been summarized previously in Table 2. The etiology and epidemiology of CAP in cancer and transplant patients is addressed elsewhere in this issue.

Bacterial pneumonia

Bacterial pneumonia continues to be an important problem in patients with HIV infection. Pneumonia remains the chief cause of hospitalization for patients with HIV/AIDS, even in the era of combination antiretroviral therapy (ART) [35]. The incidence of bacterial pneumonia in HIV patients ranges from 2 to 19 cases per 100 patients/year [36–38]. Low CD4 cell counts, injection drug use, prior sinusitis, and
prior lower respiratory tract bacterial infection are risk factors for bacterial pneumonia in patients with HIV infection [38,39], whereas trimethoprim-sulfamethoxazole prophylaxis is associated with a lower risk of bacterial pneumonia [38,40,41]. Several studies have confirmed bacterial pneumonia to be the most common pulmonary complication in patients with HIV/AIDS. *S pneumoniae*, *S aureus*, *H influenzae*, and *M pneumoniae* are the most frequent pathogens identified [5,38,42,43]. In addition, there is a trend toward higher mortality and more frequent presentation of severe pneumonia caused by *P aeruginosa*, especially in patients with advanced HIV/AIDS [36,44].

**Mycobacterial pneumonia**

Among the types of mycobacterial infections associated with HIV/AIDS, *M tuberculosis* is considered the most prevalent and important problem worldwide. The incidence of tuberculosis ranges from 1.4 to 2.2 cases per 100 person-years to 7.7 to 16.2 cases per 100 person-years, depending on the geographic location, prevalence rates of tuberculin test reactivity, and the demographic characteristics of the population [45,46]. It is estimated that 6000 to 9000 new cases of tuberculosis occur annually in the United States in patients with HIV/AIDS [45,47]. HIV-infected patients have markedly increased risks
for primary infection, reactivation of tuberculosis, and second episodes of tuberculosis from exogenous reinfection [47]. Most cases present as pulmonary infections, with case rates extraordinarily high among indigent patients and users of illicit drugs [47]. Clinical studies have shown the detrimental effects of tuberculosis on the course of HIV infection, with a twofold higher mortality in dual-infected hosts when compared with HIV-infected patients without tuberculosis, independent of CD4 cell count [47]. The degree of immunosuppression is the most important predictor of survival in HIV-infected patients with tuberculosis [48].

Notable nontuberculous mycobacterial infections in HIV-infected patients occur from *M. kansasii*, *M. scrofulaceum*, *M. terrae*, *M. gordonae*, *M. chelonae*, *M. genavense*, *M. xenopi*, and *M. fortuitum*. Although rare, isolated pulmonary *M. avium complex* (MAC) infection has been reported in 20 patients with HIV infection [49].

**Fungal pneumonia**

With the advent of combination ART, the incidence of opportunistic infections in hosts with HIV infection has substantially declined [50]. Likewise, the incidence of opportunistic fungal infections is approximately 20% to 25% of the incidence seen in the mid-1990s. Despite the decline in the incidence of opportunistic infections, fungal infections are still common in patients with advanced HIV disease. Such infections occur in patients who are long-term non-presenters, who are nonadherent to ART, or who do not seek medical care [50,51]. *P. jiroveci* pneumonia (PCP) remains the most common opportunistic infection, whereas the incidence of pneumonia owing to *Cryptococcus neoformans*, *Histoplasma capsulatum*, *Coccidioides immitis*, and *Penicillium marneffei* varies greatly depending on the geographic location (see Table 2) [50,51]. As is true for tuberculous and nontuberculous mycobacterial infections, some cases of fungal pneumonias have been associated with the use of ART and the subsequent immune restoration from AIDS [51]. Because this syndrome may mask the clinical presentation of typical and atypical pneumonic infections, a high index of suspicion is necessary for early diagnosis.

**Miscellaneous community-acquired pneumonia pathogens in HIV/AIDS**

Infections from cytomegalovirus, herpes simplex virus, respiratory syncytial virus, and influenza virus readily occur in patients with HIV/AIDS. The true incidence and prevalence of these pathogens as causes of CAP in HIV-infected patients are unknown. In severely immunosuppressed hosts with PCP, coexisting pulmonary infection has been reported in as many as 40% of cases [52,53].

**Special considerations**

In recent years, newer agents such as Hantavirus, severe acute respiratory syndrome (SARS), and avian influenza have been identified as causes of CAP. Although rare, an isolated case or outbreak from agents of bioterrorism is plausible (www.who.int and www.cdc.gov). Pneumonic presentations of bioterrorist activity are likely attributed to *Bacillus anthracis*, *Yersinia pestis*, or *Francisella tularensis*. Any suspected case should be treated as an epidemiologic emergency. The local health department should be notified. Because these agents may be transmittable from person to person, a high index of suspicion will lead to prompt diagnosis and proper treatment. Initial assessment of all patients with CAP should include a travel history, animal exposures, and occupational risk (see Table 3).

**Summary**

The growing list of etiologic agents associated with CAP and the growing number of the at-risk population continue to challenge existing diagnostic modalities for this lower respiratory tract infection. Physicians should be aware of unusual presentations of common causes of CAP as well as common presentations of unusual causes of CAP. Empiric treatment remains the norm in patients with CAP.

**References**

[1] Bartlett JG, Mundy LM. Community-acquired pneumonia. N Engl J Med 1995;333:1618–24.
[2] File Jr TM. The epidemiology of respiratory tract infections. Semin Respir Infect 2000;15:184–94.
[3] Bartlett JG, Breiman RF, Mandell LA, et al. Community-acquired pneumonia in adults: guidelines for management. Clin Infect Dis 1998;26:811–38.
[4] File Jr TM, Tan JS, Plouffe JF. The role of atypical pathogens: *Mycoplasma pneumoniae*, *Chlamydia pneumoniae*, and *Legionella pneumophila* in respiratory infection. Infect Dis Clin North Am 1998;12:569–92.
[5] Mundy LM, Auwaerter PG, Oldach D, et al.
Community-acquired pneumonia: impact of immune status. Am J Respir Crit Care Med 1995;152:1309–15.

[6] Mandell LA, Marrie TJ, Grossman RF, et al. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. Clin Infect Dis 2000;31:383–421.

[7] Marrie TJ, Durant H, Yates L. Community-acquired pneumonia requiring hospitalization: 5-year prospective study. Rev Infect Dis 1989;11:586–99.

[8] Burman LA, Trollfors B, Andersson B, et al. Diagnosis of pneumonia by cultures, bacterial and viral antigen detection tests, and serology with special reference to antibodies against pneumococcal antigens. J Infect Dis 1991;163:1087–93.

[9] Torres A, Serra-Batllés J, Ferrer A, et al. Severe community-acquired pneumonia: epidemiology and prognostic factors. Am Rev Respir Dis 1996;144:312–8.

[10] Fine MJ, Smith MA, Carson CA, et al. Prognosis and outcomes of patients with community-acquired pneumonia. JAMA 1994;331:643–8.

[11] Hofmann J, Cetron MS, Farley MM, et al. The epidemic of pneumococcal disease in an overcrowded, inadequately ventilated jail. N Engl J Med 1994;331:1987–93.

[12] Nuorti JP, Butler JC, Farley MM, et al. Cigarette smoking and invasive pneumococcal disease. N Engl J Med 2000;342:681–9.

[13] Hofmann J, Reicher MR, Dominguez EA, et al. An epidemic of pneumococcal disease in a Spanish multicenter study. Am J Respir Crit Care Med 1999;20:499–506.

[14] Torres A, Dorca J, Zalacain R, et al. Community-acquired pneumonia in chronic obstructive pulmonary disease: a Spanish multicenter study. Am J Respir Crit Care Med 1996;154:1456–61.

[15] Gage BF, Reischl MR, Dominguez EA, et al. Drug-resistant pathogens in community- and hospital-acquired pneumonia. Clin Chest Med 1995;16:111–20.

[16] Hatchette TF, Gupta R, Marrie TJ. Pneumonia due to Staphylococcus aureus. Chest 1997;112:826–31.

[17] Al-Ujaili B, Nafziger DA, Saravolatz L. Pneumonia and pleural space. Clin Infect Dis 1993;16(Suppl 4):S248–55.

[18] Hatchette TF. Gram-positive pneumonia. In: Pennington JE, editor. Respiratory infections: diagnosis and management. 3rd edition. New York: Raven Press; 1994. p. 349–67.

[19] Iwahara T, Ichiyama S, Nada T, et al. Clinical and epidemiologic investigations of nosocomial pulmonary infections caused by methicillin-resistant Staphylococcus aureus. Chest 1994:105:826–31.

[20] Al-Ujaili B, Nafziger DA, Saravolatz L. Pneumonia due to Staphylococcus aureus. Infection. Clin Chest Med 1995;16:111–20.

[21] Hatchette TF, Gupta R, Marrie TJ. Pseudomonas aeruginosa community-acquired pneumonia in previously healthy adults: case report and review of the literature. Clin Infect Dis 2000;31:1349–56.

[22] Bartlett JG. Anaerobic bacterial infections of the lung and pleural space. Clin Infect Dis 1993;16(Suppl 4):S248–55.

[23] Bartlett JG. Anaerobic bacterial pneumonitis. Am Rev Respir Dis 1979;119:19–23.

[24] Pollock HM, Hawkins EL, Bonner JR, et al. Diagnosis of bacterial pulmonary infections during quantitative protected catheter cultures obtained during bronchoscopy. J Clin Microbiol 1983;17:255–9.

[25] Kuo CC, Jackson LA, Campbell LA. Chlamydia pneunmiae (TWAR). Clin Microbiol Rev 1995;8:451–61.

[26] Gaydos CA, Eiden JJ, Oldach D, et al. Diagnosis of Chlamydia pneunmiae infection in patients with community-acquired pneumonia by polymerase chain reaction enzyme immunoassay. Clin Infect Dis 1994;19:157–60.

[27] Stout JE, Yu VL. Legionellosis. N Engl J Med 1997;337:682–7.

[28] Marrie TJ, Grossman RF, et al. Community-acquired bacterial pneumonia in human immunodeficiency virus-infected patients. Am J Respir Crit Care Med 2000;162:2063–8.
Boschini A, Smacchia C, Di Fine M, et al. Community-acquired pneumonia in a cohort of former injection drug users with and without human immunodeficiency virus infection: incidence, etiologies and clinical aspects. Clin Infect Dis 1996;23:107–13.

Hirschtick RE, Glassroth J, Jordan MC, et al. Bacterial pneumonia in persons infected with the human immunodeficiency virus. N Engl J Med 1995;333:845–51.

Baril L, Astagneau P, Nguyen J, et al. Pyogenic bacterial pneumonia in human immunodeficiency virus-infected inpatients: a clinical, radiological, microbiological, and epidemiological study. Clin Infect Dis 1998;26:964–71.

Navin TR, Rimland D, Lennox JL, et al. Risk factors for community-acquired pneumonia among persons infected with human immunodeficiency virus. Clin Infect Dis 2000;181:158–64.

Hardy WD, Feinberg J, Finkelstein DM, et al. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with human immunodeficiency syndrome. N Engl J Med 1992;327:1842–8.

Afessa B, Green W, Chiao J, et al. Pulmonary complications of HIV infection: autopsy findings. Chest 1998;113:1225–9.

Park DR, Sherbin VL, Goodman MS, et al. The etiology of community-acquired pneumonia at an urban public hospital: influence of human immunodeficiency virus infection and initial severity of illness. Clin Infect Dis 2001;184:268–77.

Manfredi R, Nanetti A, Ferri M, et al. Pseudomonas spp complications in patients with HIV disease: an eight-year clinical and microbiology survey. Eur J Epidemiol 2000;16:111–8.

Markowitz N, Hansen NI, Hopewell PC, et al. Incidence of tuberculosis in the United States among HIV-infected persons: the pulmonary complications of HIV Infection Study Group. Ann Intern Med 1997;126:123–32.

Dupon M, Texier-Maugein L, Leroy V, et al. Tuberculosis and HIV infection: a cohort study of incidence and susceptibility to tuberculosis drugs, Bordeaux, 1985–1993. AIDS 1995;9:577–83.

Havlir DV, Barnes PF. Tuberculosis in patients with human immunodeficiency virus infection. N Engl J Med 1999;340:367–73.

Whalen C, Hosburgh Jr CR, Hom D, et al. Site of disease and opportunistic infection predict survival in HIV-associated tuberculosis. AIDS 1997;11:455–60.

Salama C, Policar M, Venkataraman M. Isolated pulmonary Mycobacterium avium complex infection in patients with human immunodeficiency virus infection: case reports and literature review. Clin Infect Dis 2003;37:e35–40.

Kaplan JE, Hanson D, Dworkin MS, et al. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis 2000;30:55–14.

Apisarnthanarak A, Powderly WG. Treatment of acute cryptococcal disease. Expert Opin Pharmacother 2001;2:1259–68.

Orlovic D, Kularatne R, Ferraz V, et al. Dual pulmonary infection with Mycobacterium tuberculosis and Pneumocystis carinii in patients infected with human immunodeficiency virus. Clin Infect Dis 2001;32:289–94.

Allegra CJ, Chabner BA, Tuazon CV, et al. Trimetrexate in the treatment of Pneumocystis carinii pneumonia in patients with acquired immunodeficiency syndrome. N Engl J Med 1987;317:978–85.